Hemostasis and Stem Cell Therapy in Myocardial Infarction

Abstract

Introduction Myocardial infarction (MI) results in significant cardiac damage due to the heart's limited self-repair capacity. Stem cell therapy has emerged as a promising strategy for cardiac repair. This literature review synthesizes recent evidence on the evolving mechanisms, clinical potential, and persistent challenges of this therapeutic approach.

Methods This comprehensive literature review analyzes and synthesizes findings from eight key articles published between 2009 and 2014. The analysis tracks the evolution of stem cell research for MI, from early concepts of direct regeneration to the current focus on paracrine signaling, immunomodulation, and clinical trial results.

Results The primary therapeutic mechanism is now attributed to paracrine effects and immunomodulation rather than direct cellular regeneration. Transplanted stem cells release factors that promote angiogenesis, reduce fibrosis, and modulate the immune environment to a pro-reparative state. Research has evolved to include various cell types, such as induced pluripotent stem cells (iPSCs), to overcome ethical and safety challenges. Despite promising preclinical findings, clinical trial results have been inconsistent, with benefits varying based on cell type, delivery method, and patient selection.

Discussion The synthesized evidence marks a paradigm shift in understanding stem cell therapy for MI, moving from a cell-replacement model to a paracrine-based model of repair. This change suggests that future success depends on optimizing the secretome and immunomodulatory functions of the chosen cells for the specific patient and disease stage.

Conclusion Stem cell therapy holds significant potential for treating MI, primarily through paracrine and immunomodulatory mechanisms. To translate this potential into routine practice, future research must focus on standardizing protocols for cell type, dosage, and delivery to overcome inconsistent clinical outcomes and improve therapeutic efficacy.